Search | IOVS | ARVO Journals

Showing 1 – 20 of 29

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Assessing Retinal Vascular Leakage with Optical Coherence Tomography Angiography (OCTA) and Deep Convolutional Neural Networks

Jovi Wong; John Park; Brianna Lu; Neda Pirouzmand; David T Wong

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2331.

ARVO Annual Meeting Abstract June 2022

Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells

Ping Yang; Rose Trimpey-Warhaftig; Jin Mo Koo; John Park; Hampar Karageozian; Vicken H Karageozian; Zixuan Shao; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3041 – F0412.

ARVO Annual Meeting Abstract June 2022

Risuteganib-directed staining localizes in the Retinal Pigment Epithelium of Retinal Tissue from Aged, but not Young, Mice

Jin Mo Koo; Connor Call; Dan Zhou; John Park; Hampar Karageozian; Vicken H Karageozian; Zixuan Shao; Julia A. Kornfield

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4414 – F0093.

ARVO Annual Meeting Abstract June 2021

Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina

Zixuan Shao; Sean F. Hackett; Raquel Formica; Yogita Kanan; Dan Zhou; John Y Park; Hampar L Karageozian; Vicken H Karageozian; Peter A Campochiaro; Julia A. Kornfield

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):186.

ARVO Annual Meeting Abstract June 2021

Cell Viability and Transcriptome Changes Associated with Hydrogen Peroxide and Risuteganib Exposure in Human Retinal Cells In Vitro

Marilyn Chwa; Zixuan Shao; Shari Atilano; John Y Park; Hampar Karageozian; Vicken Karageozian; M. Cristina Kenney

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3000.

ARVO Annual Meeting Abstract June 2021

Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells

Ping Yang; Nicholas Anthony Besley; Scott W Lallier; Zixuan Shao; John Y Park; Hampar Karageozian; Vicken Karageozian; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2697.

ARVO Annual Meeting Abstract June 2021

Neuroprotective Effect of Risuteganib on Retinal Neurons in an Excitotoxic Injury Cell Culture Model and a Mechanical Injury Rat Model

Lenin David Ochoa-de la Paz; Roberto Gonzalez-Salinas; Zixuan Shao; John Y Park; Hampar L Karageozian; Vicken H Karageozian; Hugo Quiroz-Mercado

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3003.

Retinal Cell Biology August 2020

Risuteganib Protects against Hydroquinone–induced Injury in Human RPE Cells

PDF

Ping Yang; Zixuan Shao; Nicholas A. Besley; Samantha E. Neal; Kristen L. Buehne; John Park; Hampar Karageozian; Vicken Karageozian; Ian T. Ryde; Joel N. Meyer; Glenn J. Jaffe
TAGS: combined modality therapy, retinal pigment cell, wounds and injuries, actins, rna-seq
Invest. Ophthalmol. Vis. Sci.. 2020; 61(10):35. https://doi.org/10.1167/iovs.61.10.35

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Risuteganib Modifies Hydroquinone-regulated Gene Expression and Protects against Hydroquinone-induced Cytotoxic Effects in Human RPE Cells

Ping Yang; Zixuan Shao; Nicholas Besley; John Y Park; Hampar Karageozian; Vicken Karageozian; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3117.

ARVO Annual Meeting Abstract June 2020

Mechanism of Action of Risuteganib for Retinal Diseases through Protection of Retinal Pigment Epithelium (RPE) and Enhancement of Mitochondrial Functions

Dan Zhou; Marilyn Chwa; Zixuan Shao; Jin Mo Koo; John Y Park; Hampar L Karageozian; Vicken H Karageozian; Cristina M Kenney; Julia A Kornfield

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4949.

ARVO Annual Meeting Abstract June 2020

Clinical outcomes of Descemet membrane endothelial keratoplasty performed in eyes with comorbid keratoconus and corneal endothelial dysfunction

Philip Dockery; Jack Parker; Renuka Birbal; Maya Tong; John Parker; Katelyn Joubert; Gerrit Melles

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3559.

ARVO Annual Meeting Abstract July 2018

Cytoprotective effect of ALG-1001 peptide (Luminate) on human retinal pigment epithelial cells exposed to oxidative injury. A novel functional-outcome for an anti-VEGF agent.

Marco A Beltran; Ruben Zamora-Alvarado; Roberto Gonzalez-Salinas; Rosario Gulias-Cañizo; Hugo Quiroz-Mercado; LUIS F HERNANDEZ; Hampar Karageozian; Vicken H Karageozian; John Y Park; Lenin Ochoa-de la Paz

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1465.

ARVO Annual Meeting Abstract July 2018

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Hugo Quiroz-Mercado; David S Boyer; Peter A Campochiaro; Jeffrey S. Heier; Peter K Kaiser; Julie Kornfield; Baruch D Kuppermann; Vicken H Karageozian; Hampar L Karageozian; Lisa Karageozian; John Y Park; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1960.

ARVO Annual Meeting Abstract June 2017

Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration

Hugo Quiroz-Mercado; Jose Luis Guerrero-Naranjo; Roberto Gonzalez-Salinas; Luis F Hernandez-Zimbron; Ruben Zamora; Rosario Gulías-Cañizo; Lenin Ochoa-De la Paz; Lisa Karageozian; Vicken Karageozian; Linda Kutscher; John Y Park; Hampar Karageozian

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1943.

ARVO Annual Meeting Abstract June 2017

Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate ® in patients with diabetic macular edema

Peter K Kaiser; David S Boyer; Peter A Campochiaro; Jeffrey Heier; Julie Kornfield; Baruch D Kuppermann; Hugo Quiroz-Mercado; Lisa Karageozian; Linda Kutscher; Mary Karpus; John Y Park; Hampar L Karageozian; Vicken Karageozian

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2029.

ARVO Annual Meeting Abstract June 2015

Tactile acuity determined with vibration motors for use in a sensory substitution device for the blind

H. Christiaan Stronks; Daniel John Parker; Nick M Barnes

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2920.

ARVO Annual Meeting Abstract June 2015

Incidence of Herpes Simplex Eye Disease: Results from the Pacific Ocular Inflammation (POI) Study

Durga S Borkar; Vivien M Tham; John V Parker; Aileen Uchida; Aleli C Vinoya; Nisha Acharya

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5755.

ARVO Annual Meeting Abstract June 2015

Validation of ICD-9 Codes Used in the Pacific Ocular Inflammation (POI) Study

Priya Janardhana; Nisha Acharya; Durga S Borkar; Vivien M Tham; John V Parker; Aleli C Vinoya; Aileen Uchida; Erica Browne

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5759.

ARVO Annual Meeting Abstract April 2014

Association between Statin Use and Uveitis: Results from the Pacific Ocular Inflammation Study

Durga Borkar; Vivien Tham; John V Parker; Aileen Uchida; Aleli C Vinoya; Nisha Acharya

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1862.

ARVO Annual Meeting Abstract April 2014

Dysregulation of Macrophage Cholesterol Homeostasis in AMD Pathogenesis

Abdoulaye Sene; Aslam A Khan; Doug Cox; Rei E I Nakamura; Nicole Zapata; Itay Chowers; John S Parks; Rajendra S Apte

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):84.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Assessing Retinal Vascular Leakage with Optical Coherence Tomography Angiography (OCTA) and Deep Convolutional Neural Networks

Cellular Uptake of Risuteganib via Endocytosis in Cultured Human RPE Cells

Risuteganib-directed staining localizes in the Retinal Pigment Epithelium of Retinal Tissue from Aged, but not Young, Mice

Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina

Cell Viability and Transcriptome Changes Associated with Hydrogen Peroxide and Risuteganib Exposure in Human Retinal Cells In Vitro

Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells

Neuroprotective Effect of Risuteganib on Retinal Neurons in an Excitotoxic Injury Cell Culture Model and a Mechanical Injury Rat Model

Risuteganib Protects against Hydroquinone–induced Injury in Human RPE Cells

Risuteganib Modifies Hydroquinone-regulated Gene Expression and Protects against Hydroquinone-induced Cytotoxic Effects in Human RPE Cells

Mechanism of Action of Risuteganib for Retinal Diseases through Protection of Retinal Pigment Epithelium (RPE) and Enhancement of Mitochondrial Functions

Clinical outcomes of Descemet membrane endothelial keratoplasty performed in eyes with comorbid keratoconus and corneal endothelial dysfunction

Cytoprotective effect of ALG-1001 peptide (Luminate) on human retinal pigment epithelial cells exposed to oxidative injury. A novel functional-outcome for an anti-VEGF agent.

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration

Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate ® in patients with diabetic macular edema

Tactile acuity determined with vibration motors for use in a sensory substitution device for the blind

Incidence of Herpes Simplex Eye Disease: Results from the Pacific Ocular Inflammation (POI) Study

Validation of ICD-9 Codes Used in the Pacific Ocular Inflammation (POI) Study

Association between Statin Use and Uveitis: Results from the Pacific Ocular Inflammation Study

Dysregulation of Macrophage Cholesterol Homeostasis in AMD Pathogenesis

To View More...

You must be signed into an individual account to use this feature.